AgroScience Capital AG develops proprietary active ingredients for crop protection, focusing on fungicidal applications that effectively control a broad spectrum of phytopathogens affecting major crops. The startup addresses the challenges of declining crop yields due to climate change and resistance issues, enhancing agricultural sustainability through environmentally friendly innovations in fertilizers and pest management.
Funding
$1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Global crop yields are threatened by climate change, arable land limitations, and the evolution of resistance in phytopathogens, leading to significant pre- and post-harvest losses. Existing crop protection methods face efficacy issues, necessitating innovative solutions for sustainable agriculture.
Solution
AgroScience Capital AG develops and patents novel active ingredients for crop protection, with a focus on fungicidal applications. Their proprietary technology effectively controls a broad spectrum of commercially relevant phytopathogens affecting major crops. By providing innovative solutions in pest management, AgroScience Capital AG aims to enhance agricultural sustainability and mitigate the impact of climate change on crop production. The company's research and development efforts are geared towards creating environmentally friendly solutions for the agriculture industry.
Target Audience
The primary target audience includes agricultural businesses, crop protection companies, and farmers seeking innovative and sustainable solutions for pest management and improved crop yields.
Features
- Proprietary active ingredient from the alkylene guanidine group with a unique CAS number.
- Broad disease control spectrum effective against pathogens such as Venturia inaequalis, Alternaria alternata, and Fusarium species.
- ≈ 30 international patents granted, including in major agricultural markets like China, India, Brazil, US, Canada, Japan, and Europe.
- Improved "t.k." design for enhanced in-vitro and in-vivo efficacy.